ИСИрина Вячеславовна Сильнова

Ирина Вячеславовна Сильнова

*This is an algorithmically generated author record based on publicly available information.

Ирина Вячеславовна Сильнова has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative efficacy of methods for early diagnosis of myocardial involvement in Duchenne and Becker muscular dystrophies

    by Валентина Геннадьевна Каверина, Наталия Андреевна Сдвигова, Ирина Вячеславовна Сильнова, София Георгиевна Попович, Евгения Владимировна Увакина, Елена Николаевна Басаргина, Людмила Михайловна Кузенкова

    Introduction. Cardiomyopathy is the leading cause of mortality in dystrophinopathies. Standard screening methods often fail to detect early preclinical changes. The aim of the study was a comparative assessment of the diagnostic value of modern methods (global longitudinal strain — GLS, 24-hour ECG monitoring — Holter monitoring, myocardial damage biomarkers) in detecting early cardiac dysfunction.Materials and methods. A prospective cross-sectional study included thirty one patient with Duchenne/Becker muscular dystrophy (DMD/BMD). All patients underwent comprehensive assessment including echocardiography with GLS analysis, 24-hour Holter monitoring, determination of NT-proBNP and troponin I levels.Results. Reduced left ventricular ejection fraction (LVEF < 50%) was detected in 5 patients (16.1%). In patients with preserved LVEF, subclinical reduction in GLS was noted in 68.8%. Holter monitoring detected tachycardia significantly more often than a single ECG recording (p < 0.050), as well as a combination of tachycardia with reduced heart rate variability and high ventricular ectopic activity. The NT-proBNP level was significantly higher in the group with LVEF < 50% (279.8 [73.28; 844.8] vs. 60.83 [34.24; 104.5] pg/mL, p = 0.020).Conclusion. Speckle-tracking echocardiography and 24-hour Holter monitoring have significantly higher sensitivity in detecting preclinical cardiomyopathy in DMD/BMD compared to standard screening. Their combined use with the determination of NT-proBNP and troponin I allows the risk stratificating and justifying early initiation of cardioprotective therapy.Contributions:Kaverina V.G. — writing the text;Sdvigova N.A. — writing, editing the text;Silnova I.V. — writing, editing the text;Popovich S.G. — writing, editing the text;Uvakina E.V. — writing, editing the text;Basargina E.N. — conception and design of the article, writing the text, editing;Kuzenkova L.M. — conception and design of the article, writing the text, editing.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: December 1, 2025Accepted: December 22, 2025Published: January 31, 2026


  • Open Access

    A Unique Case of a Child with Two Rare Hereditary Diseases: Familial Dilated Cardiomyopathy and Arterial Calcification

    by Yulia Burykina, Daria Chudakova, Olga Zharova, Elena Basargina, Irina Silnova, Natalia Sdvigova, Leila Gandaeva, Yulia Davydova, Valentina Kaverina, Ilya Zhanin, et al.

    Here, we present a unique case of the combination of two rare hereditary diseases—a familial form of dilated cardiomyopathy (DCM) and arterial calcification (AC)—in a 10-month-old boy. DCM was caused by a novel pathogenic nucleotide variant (NV) c.542G>T in the MYH7 gene, and AC was caused by biallelic nucleotide variants c.3421C>T and c.4015C>T in the ABCC6 gene. NVs were identified by the next-generation sequencing (NGS) of a broad panel of 404 genes potentially involved in cardiovascular disorders and subsequently validated by Sanger sequencing in the proband and his parents. Cardiologic examinations confirmed the familial nature of cardiomyopathy and the pathogenicity of variant c.542G>T in MYH7 gene. This case highlights the clinical utility of NGS in identifying complex co-existing hereditary conditions and emphasizes the need for the comprehensive genetic testing of patients with atypical clinical presentations.